Coronary Bifurcation Stenting (COBIS) Registry in South Korea

The COBIS registry is multi-center, real-world registry of drug-eluting stenting in coronary bifurcation lesions in South Korea.

The aim of the study was to find out the current status of bifurcation drug-eluting stenting and determine the prognostic factors for long-term outcome in South Korea.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronary Bifurcation Lesion

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Samsung Medical Center

Seoul, 135-710, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age >= 18 years
Any type of de novo bifurcation lesion with a parent vessel >= 2.5 mm and side branch>= 2.0 mm by visual estimation
Treated with drug-eluting stent

Exclusion criteria

Cardiogenic Shock
ST elevation MI within 48hours
Expected survival less than 1 year
Left main bifurcation
Allergy to the antiplatelets

Treatment and study plan

Primary outcomes

Incidence of the composite outcome of all-cause death, MI, or any PCI/CABG

Time frame: 3 years

Secondary outcomes

Incidence of stent thrombosis, and periprocedural MI

Time frame: 3 years

Sponsors and collaborators

Lead sponsor

Samsung Medical Center

Other

Registry information

Acronym: COBIS

Important dates

Study start: 2004
Primary completion: 2008
Study completion: 2008
First posted: Feb 26, 2009
Registry last updated: Jul 17, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed